Comparable stake leader
MONTANOVA CAPITAL, LLC
SEC ownership of Benitec Biopharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001808898.
Disclosed value leader
MONTANOVA CAPITAL, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- BNTC on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
MONTANOVA CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
MONTANOVA CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001808898
- Issuer location
- Hayward, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Benitec Biopharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MONTANOVA CAPITAL, LLC
Disclosed value leader
MONTANOVA CAPITAL, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 44%
13D/G row: MONTANOVA CAPITAL, LLC
Showing 1-8 of 50 holder rows.
Quick read
MONTANOVA CAPITAL, LLC leads the comparable SEC ownership view at 44%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MONTANOVA CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
MONTANOVA CAPITAL, LLC
44%
FRANKLIN RESOURCES INC
11%
Janus Henderson Group Ltd.
10%
RA CAPITAL MANAGEMENT, L.P.
5.5%
HBM Healthcare Investments (Cayma...
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC |
13D/G
3/4/5
13F
SUVRETTA CAPITAL MANAGEMENT, LLC · Director, 10%+ Owner · Company
|
44%
|
$249,200,088
17,761,945 shares
|
+$30,000,153 | 07 Nov 2025 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
11%
|
$50,561,782
3,751,709 shares
|
-$5,287,404 | 31 Dec 2025 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
10%
|
$44,484,293
3,382,836 shares
|
-$292,158,468 | 28 Nov 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$24,753,000
1,850,000 shares
|
— | 30 Jun 2026 |
| HBM Healthcare Investments (Cayman) Ltd. |
13D/G
|
4.5%
|
$14,156,282
1,041,669 shares
|
$0 | 31 Dec 2024 |
| Nantahala Capital Management, LLC |
13F
13D/G
Company
|
4.4%
from 13D/G
|
$19,914,404
1,488,371 shares
|
— | 30 Jun 2026 |
| Jupiter Topco LLC |
13F
Company
|
7%
|
$33,113,388
2,478,547 shares
|
— | 30 Jun 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
6%
|
$28,374,591
2,120,672 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$22,442,099.
Buys
$22,442,099
Insiders: 1
Sells
$0
Insiders: 0
Net
+$22,442,099
Shares: +1,671,845
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,671,845
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 190,364 | 0 | $2,442,105 | $0 | +$2,442,105 |
| 9-12 | 1,481,481 | 0 | $19,999,994 | $0 | +$19,999,994 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Benitec Biopharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
MONTANOVA CAPITAL, LLC
Net 12M change
+$22,442,099
Latest report
29 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | Director, 10%+ Owner | $24,839,216 | +$22,442,099 | +936% | Filing P/S | 23 Dec 2025 |
| Steven Michael Oliveira | 10%+ Owner | $3,044,300 | Filing P/S | 28 Apr 2021 | ||
| J. Kevin Buchi | Director | $954,829 | Mixed | 29 Jun 2026 | ||
| Sophie Mukadam | Chief Operating Officer | $67,680 | Mixed | 18 Nov 2025 | ||
| Peter Francis | Director | Mixed | 01 Dec 2025 | |||
| Sharon Mates | Director | Mixed | 22 Jan 2026 | |||
| Megan Boston | Chief Financial Officer, Director | Mixed | 18 Nov 2025 | |||
| David Matthew Friedman | Director | Mixed | 26 May 2026 | |||
| Kishan Mehta | Director | Mixed | 01 Dec 2025 | |||
| Edward F. Smith | Director | Mixed | 01 Dec 2025 | |||
| Jerel A. Banks | Chief Executive Officer, Director | Mixed | 18 Nov 2025 |
Recent insider transactions for Benitec Biopharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| J. Kevin Buchi | BNTC | Common Stock | Gift | -49.9% | -51,813 | 52,097 | 29 Jun 2026 | Direct | ||
| David Matthew Friedman | BNTC | Options (right to buy) | Award | 35,000 | 35,000 | 26 May 2026 | Direct | |||
| Sharon Mates | BNTC | Options (right to buy) | Award | 31,500 | 31,500 | 22 Jan 2026 | Direct | |||
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 0.8% | $1,040,081 | $13.44 | 77,387 | 9,700,195 | 29 Dec 2025 | See footnotes |
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 0.18% | $220,552 | $13.10 | 16,836 | 9,634,395 | 26 Dec 2025 | See footnotes |
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 0.52% | $642,500 | $12.85 | 50,000 | 9,620,075 | 23 Dec 2025 | See footnotes |
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 0.2% | $236,067 | $12.08 | 19,542 | 9,577,475 | 22 Dec 2025 | See footnotes |
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 0.17% | $188,088 | $11.48 | 16,384 | 9,560,825 | 19 Dec 2025 | See footnotes |
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 0.11% | $114,817 | $11.24 | 10,215 | 9,546,875 | 18 Dec 2025 | See footnotes |
| Sharon Mates | BNTC | Options (right to buy) | Award | 3,500 | 3,500 | 01 Dec 2025 | Direct | |||
| Kishan Mehta | BNTC | Options (right to buy) | Award | 35,000 | 35,000 | 01 Dec 2025 | Direct | |||
| Edward F. Smith | BNTC | Options (right to buy) | Award | 35,000 | 35,000 | 01 Dec 2025 | Direct | |||
| Peter Francis | BNTC | Options (right to buy) | Award | 35,000 | 35,000 | 01 Dec 2025 | Direct | |||
| J. Kevin Buchi | BNTC | Options (right to buy) | Award | 35,000 | 35,000 | 01 Dec 2025 | Direct | |||
| Sophie Mukadam | BNTC | Options (right to buy) | Award | 500,000 | 500,000 | 18 Nov 2025 | Direct | |||
| Jerel A. Banks | BNTC | Options (right to buy) | Award | 450,000 | 450,000 | 18 Nov 2025 | Direct | |||
| Megan Boston | BNTC | Options (right to buy) | Award | 200,000 | 200,000 | 18 Nov 2025 | Direct | |||
| Suvretta Capital Management, Llc | BNTC | Common stock, par value $0.0001 per share | Purchase | 18.4% | $19,999,994 | $13.50 | 1,481,481 | 9,538,175 | 07 Nov 2025 | See footnotes |
| Sharon Mates | BNTC | Options (right to buy) | Award | 28,517 | 28,517 | 05 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.